ASH 2025: Prophylactic Tocilizumab Reduces CRS

At ASH 2025, Astrid Hundebøll Torpe presented new data on the use of prophylactic tocilizumab during ciltacabtagene step-up dosing in relapsed and refractory multiple myeloma. The preventive approach reduced cytokine release syndrome without affecting treatment effectiveness or safety. The results indicate that a simple intervention may help support safer and potentially outpatient administration.